Back Hepatitis B Hepatitis B Topics HBV Treatment

Hepatitis B Testing Should Be Done Before and During Hepatitis C Treatment

People considering treatment for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as successful elimination of hepatitis C virus (HCV) can reactivate HBV and potentially worsen liver disease, according to recent updates to American and European hepatitis C treatment guidelines.

alt

Read more:

EASL 2016: Hepatitis B Treatment Linked to Colorectal and Cervical Cancer

People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have an overall higher rate of malignancies, but did show an increased incidence of colorectal and cervical cancer, underlining the need for regular screening, according to a study presented at the recent EASL International Liver Congress in Barcelona.

alt

Read more:

EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity

NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.

alt

Read more:

EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B

Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.

alt

Read more:

EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more: